Fred E. Cohen
CIK: 0001339358
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jun 12, 2026CDNA
CareDx, Inc.
Award(A)Direct9.8K shares- - Jun 9, 2026NTLA
Intellia Therapeutics, Inc.
Award(A)Direct9.2K shares- - May 27, 2026KYTX
Kyverna Therapeutics, Inc.
Award(A)Direct5.1K shares- - Jan 5, 2026NTLA
Intellia Therapeutics, Inc.
Purchase(P)Direct150K shares at avg. $9.35$1.4M - Jun 13, 2025CDNA
CareDx, Inc.
Award(A)Direct12.1K shares- - Jun 11, 2025NTLA
Intellia Therapeutics, Inc.
Award(A)Direct8K shares- - May 29, 2025KYTX
Kyverna Therapeutics, Inc.
Award(A)Direct16.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 12, 2026 |  CDNA CareDx, Inc. | Award(A) | 9,795 | - | $0 | Direct |
| Jun 9, 2026 |  NTLA Intellia Therapeutics, Inc. | Award(A) | 9,200 | - | $0 | Direct |
| May 27, 2026 |  KYTX Kyverna Therapeutics, Inc. | Award(A) | 5,093 | - | $0 | Direct |
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | Purchase(P) | 150,000 | $9.35 | $1,402,500 | Direct |
| Jun 13, 2025 | CDNA CareDx, Inc. | Award(A) | 12,103 | - | - | Direct |
| Jun 11, 2025 | NTLA Intellia Therapeutics, Inc. | Award(A) | 8,000 | - | - | Direct |
| May 29, 2025 | KYTX Kyverna Therapeutics, Inc. | Award(A) | 16,634 | - | - | Direct |
1-7 of 7 transactions
About Cohen Fred E
Cohen Fred E (SEC CIK 0001339358) files insider reports with the SEC as Director of CareDx, Inc. (CDNA), Director of Intellia Therapeutics, Inc. (NTLA) and Director of Kyverna Therapeutics, Inc. (KYTX).
Signal8 holds 7 ownership filings by Cohen Fred E, all Form 4s, filed between Jun 2, 2025 and Jun 16, 2026. Those filings report 7 transactions, from May 29, 2025 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cohen Fred E's filings is in CAMBRIDGE, MA.
Recent filings by Cohen Fred E
- Jun 12, 2026: Grant or award of CDNA shares (Form 4, code A).
- Jun 9, 2026: Grant or award of NTLA shares (Form 4, code A).
- May 27, 2026: Grant or award of KYTX shares (Form 4, code A).
- Jan 5, 2026: Open-market purchase of NTLA shares (Form 4, code P).
- Jun 13, 2025: Grant or award of CDNA shares (Form 4, code A).
Other insiders filing for CareDx, Inc. (CDNA)
- Novack Jeffrey Adam, Secretary and General Counsel
- Hanna John Walter JR, President and CEO
- Kennedy Keith, CFO & COO
- Meng Jessica, Chief Commercial Officer
- Goldberg Michael, Director
- Bickerstaff George, Director